Table 2. Antibody geometric mean concentrations (GMC) after booster doses (pre and post) of acellular pertussis vaccine compained with tetanus and diphtheria toxoidsin 355 adolescent subjects with MBL wild type (A/A), heterozygotes variant type A/O (A/B, A/C, A/D) and homozygote variant type O/O (B/B, B/D, D/D, C/D, C/C).
| MBL A/A | MBL A/O | MBL O/O | P-value* | ||||
| Timing | n | GMC (95% CI) | n | GMC (95% CI) | n | GMC (95% CI) | |
| Pertussis toxin | |||||||
| before initial vaccination 10 years ago | 227 | 10.2 (8.4–12.5) | 100 | 10.03 (7.4 – 13.5) | 19 | 7.61 (3.7 – 14.0) | 0.59 |
| Month 1 | 227 | 85.6 (70.5 – 103.8) | 102 | 82.55 (63.0 – 108.1) | 16 | 62.46 (29.3 – 133.2) | 0.74 |
| Year 3 | 184 | 15.9 (13.1 – 19.2) | 74 | 17.84 (13.9 – 22.9) | 16 | 16.68 (6.7 – 24.0) | 0.50 |
| Year 5 | 165 | 12.5 (10.6 – 14.8) | 77 | 12.0 (9.5 – 15.2) | 14 | 8.3 (4.5 –15.3) | 0.51 |
| Year 10 prebooster | 54 | 8.3 (0.1 – 11.2) | 20 | 12.6 (7.3 – 22.3) | 3 | 7.1 (0.7 – 68.1) | 0.33 |
| Year 10 postbooster | 54 | 90.9 (71.6 – 115.4) | 19 | 88.7 (56.0 – 133.3) | 3 | 131.6 (9.7 – 1788) | 0.80 |
| Pertactin | |||||||
| before initial vaccination 10 years ago | 230 | 17.6 (14.3 – 21.7) | 103 | 17.5 (12.6–24.4) | 20 | 16.7 (6.9 – 40.8) | 0.97 |
| Month 1 | 232 | 386.6 (302.1 – 494.7) | 100 | 412.3 (297.8 – 570.8) | 20 | 326.4 (119.8 – 889.5) | 0.94 |
| Year 3 | 185 | 113.1 (94.3 – 135.8) | 75 | 96.5 (69.2 – 134.5) | 16 | 148.2 (75.5 – 291.2) | 0.43 |
| Year 5 | 171 | 84.8 (69.3 – 103.8) | 79 | 64.9 (46.6 – 90.5) | 14 | 62.7 (29.2 – 134.4) | 0.28 |
| Year 10 prebooster | 54 | 37.8 (27.4 –52.2) | 20 | 33.8 (17.7 – 64.5) | 3 | 54.8 (2.0 – 1503.0) | 0.91 |
| Year 10 postbooster | 54 | 585.8 (466.4 –735.7) | 19 | 450.5 (322.5 – 629.3) | 3 | 1172.0 (293.8 – 4675.0) | 0.09 |
| Filamentous hemagglutinin | |||||||
| before initial vaccination 10 years ago | 230 | 63.6 (52.8 – 74.2) | 98 | 65.6 (50.3 85.5) | 20 | 55.0 (27.2 – 111.0) | 0.93 |
| Month 1 | 232 | 637.0 (533.9 –760.0) | 103 | 667.2 (531.9 – 836.8) | 20 | 623.7 (276.5 – 1407.0) | 0.76 |
| Year 3 | 184 | 187.8 (166.1 – 212.3) | 76 | 180.9 (150.1 – 218.0) | 16 | 217.9 (140.2 – 338.8) | 0.67 |
| Year 5 | 170 | 121.8 (106.5 – 137.0) | 79 | 108.0 (87.8 –132.8) | 14 | 173.3 (98.1 – 305.9) | 0.12 |
| Year 10 prebooster | 54 | 67.6 (53.8 –84.8) | 20 | 63.0 (46.1 – 86.2) | 3 | 134.9 (47.8 – 380.7) | 0.17 |
| Year 10 postbooster | 54 | 865.0 (695.8 – 1075.0) | 19 | 532.7 (412.3 – 688.2) | 3 | 1205.0 (670.2 – 2166.0) | 0.01 |
| Tetanus toxoid | |||||||
| before initial vaccination 10 years ago | 225 | 0.6 (0.5 – 0.7) | 97 | 0.5 (0.4 – 0.6) | 19 | 0.6 (0.4 – 0.9) | 0.83 |
| Month 1 | 225 | 25.9 (23.5 – 28.5) | 97 | 23.0 (19.7 – 26.9) | 19 | 36.5 (27.8 –47.9) | 0.06 |
| Year 3 | 185 | 2.5 (2.2 – 2.8) | 76 | 2.1 (1.8 – 2.6) | 16 | 3.3 (2.5 – 4.4) | 0.08 |
| Year 5 | 171 | 2.0 (1.8 – 2.3) | 78 | 2.0 (1.6 – 2.3) | 14 | 2.1 (1.5 – 3.0) | 0.92 |
| Year 10 prebooster | 54 | 1.2 (0.8 – 1.7) | 20 | 1.2 (0.8 – 1.8) | 3 | 1.1 (0.2 – 5.8) | 0.99 |
| Year 10 postbooster | 54 | 10.1 (8.4 – 12.1) | 19 | 7.8 (4.6 – 13.1) | 3 | 14.1 (4.6 – 42.7) | 0.43 |
| Diphtheria toxin | |||||||
| before initial vaccination 10 years ago | 223 | 0.2 (0.2 – 0.2) | 97 | 0.2 (0.2 – 0.3) | 19 | 0.2 (0.1 – 0.3) | 0.54 |
| Month 1 | 225 | 7.2 (6.2 – 8.2) | 98 | 7.4 (6.0 – 9.0) | 19 | 8.5 (5.0 – 14.2) | 0.87 |
| Year 3 | 184 | 0.5 (0.5 – 0.6) | 76 | 0.6 (0.5 – 0.8) | 16 | 0.6 (0.3 – 1.0) | 0.92 |
| Year 5 | 171 | 0.4 (0.3 – 0.5) | 78 | 0.5 (0.4 – 0.7) | 14 | 0.5 (0.3 – 1.0) | 0.32 |
| Year 10 prebooster | 54 | 0.3 (0.2 – 0.4) | 20 | 0.3 (0.2 – 0.6) | 3 | 0.5 (0.1 – 2.3) | 0.67 |
| Year 10 postbooster | 54 | 5.5 (4.1 – 7.5) | 19 | 5.1 (3.6 – 7.3) | 3 | 17.3 (0.7 – 451.5) | 0.26 |
Abbreviations: GMC, geometric mean concentration; CI, confidence interval; *Kruskal-Wallis test for comparison of antibody concentrations between genotypes A/A, A/O and O/O. P-value <0.05 is considered as statistically significant.